Please be aware that the information provided is a summary of select releases made to the ASX, as evaluated and interpreted by ASX Briefs. It is important to thoroughly read the entire original release before forming an opinion, rather than relying solely on the brief overview presented here. ASX Briefs is not associated with the ASX. ASX Briefs is an experimental AI project incorporating chatGPT, and as such, does not guarantee the accuracy of the information provided.
Radiopharm Theranostics (ASX:RAD) has entered into a binding agreement to acquire Pharma15 Corporation, a private US- based venture which is developing next -generation therapeutic radiopharmaceutical s for Prostate Cancer.
The acquisition includes Professor David Ulmert and CEO Suzanne Dance, as well as KOL Professor Ken Herrmann joining RAD's Scientific Advisory Board.
The agreement includes the issue of ordinary shares and cash up -front, with some consideration deferred and some subject to the achievement of significant clinical milestones.